Proficio Capital Partners LLC Takes $482,000 Position in Medpace Holdings, Inc. $MEDP

Proficio Capital Partners LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 910 shares of the company’s stock, valued at approximately $482,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. NewEdge Advisors LLC lifted its holdings in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $296,000. Finally, M&T Bank Corp lifted its stake in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In related news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the transaction, the director owned 3,798 shares in the company, valued at $2,302,157.70. The trade was a 65.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,963 shares of company stock worth $79,364,624 in the last quarter. Company insiders own 20.50% of the company’s stock.

Medpace Trading Down 1.2%

Shares of MEDP opened at $611.57 on Friday. The firm has a market capitalization of $17.07 billion, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The stock’s fifty day simple moving average is $562.52 and its 200 day simple moving average is $493.80. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on MEDP. Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Finally, BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.